Merck sleep drug hits most goals of pivotal trials
(Reuters) - An experimental Merck & Co insomnia drug significantly reduced the time it took patients to fall asleep and helped them stay asleep longer, according to data from a pair of pivotal late-stage studies. Suvorexant, in a new class of medicines, proved to be significantly better than placebo, meeting all but one of the goals in one of the two Phase III trials with about 1,000 patients in each. Based on the data from these and other trials, Merck said it expects to file for approval of the drug later this year. ...
Source: news.yahoo.com
No comments:
Post a Comment